B-Oral Mucositis: Phase 3
B-IBD Pill: Phase 2
Kevetrin Pill: Phase 2
B-COVID: Phase 2/3
You can add a billion to the market cap for positive results on any of those trials. The odds that they all fail? Pretty darn low.
The main problem this company has had is funding, not the pipeline. The higher the stock price goes, the less of an issue funding is.
Additionally, as the name gets out and our negotiating position gets stronger, big pharma will look to make a deal more quickly on an asset like B-OM.
Go IPIX!